The Efficacy of Conbercept in Polypoidal Choroidal Vasculopathy: A Systematic Review

Overview

Journal J Ophthalmol

Publisher Wiley

Specialty Ophthalmology

Date 2020 Aug 29

PMID 32855818

Citations 2

Authors

Yimin Wang

Mengxi Shen

Jinwei Cheng

Xiaodong Sun

Peter K Kaiser

Affiliations

Soon will be listed here.

Abstract

Methods: Thirty studies with 1308 eyes were identified and included in this study. The primary outcome measures were best-corrected visual acuity (BCVA), and secondary outcomes were optical coherence tomography characteristics and polyp regression rates. The pooled results were calculated by the random-effect or fixed-effect model according to the heterogeneity of the data.

Results: Despite a large standard deviation in means (SMD) improvement for BCVA and central retinal thickness (CRT) in the conbercept group, there was no statistically significant difference in the other outcomes compared to ranibizumab and aflibercept. However, there was a greater polyp regression rate in the conbercept group at 12 months.

Conclusions: This systematic review indicates that conbercept may achieve similar BCVA and CRT improvements as ranibizumab and aflibercept, with a superior rate of polyp regression at 12 months.

Citing Articles

Combined treatment of submacular hemorrhage with low-dose subretinal recombinant tissue plasminogen activator and intravitreal conbercept.

Ma Y, Rao S, Tan Y, Du H, Sun X BMC Ophthalmol. 2024; 24(1):395.

PMID: 39237907 PMC: 11375938. DOI: 10.1186/s12886-024-03660-x.

Publication Trends of Research on Polypoidal Choroidal Vasculopathy During 2001-2020: A 20-Year Bibliometric Study.

Wang Y, Xie M, Zhang M, Zhao X, Zhu X, Wang Y Front Med (Lausanne). 2022; 8:785126.

PMID: 35174182 PMC: 8841421. DOI: 10.3389/fmed.2021.785126.

References

Morimoto M, Matsumoto H, Mimura K, Akiyama H . Two-year results of a treat-and-extend regimen with aflibercept for polypoidal choroidal vasculopathy. Graefes Arch Clin Exp Ophthalmol. 2017; 255(10):1891-1897. DOI: 10.1007/s00417-017-3718-6. View

Lee W, Iida T, Ogura Y, Chen S, Wong T, Mitchell P . Efficacy and Safety of Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy in the PLANET Study: A Randomized Clinical Trial. JAMA Ophthalmol. 2018; 136(7):786-793. PMC: 6136040. DOI: 10.1001/jamaophthalmol.2018.1804. View

Koh A, Lai T, Takahashi K, Wong T, Chen L, Ruamviboonsuk P . Efficacy and Safety of Ranibizumab With or Without Verteporfin Photodynamic Therapy for Polypoidal Choroidal Vasculopathy: A Randomized Clinical Trial. JAMA Ophthalmol. 2017; 135(11):1206-1213. PMC: 5710379. DOI: 10.1001/jamaophthalmol.2017.4030. View

Cho H, Kim K, Kim H, Han J, Kim C, Lee T . Intravitreal Aflibercept and Ranibizumab Injections for Polypoidal Choroidal Vasculopathy. Am J Ophthalmol. 2016; 165:1-6. DOI: 10.1016/j.ajo.2016.02.019. View

Sakai T, Okano K, Kohno H, Tsuneoka H . Three-year visual outcomes of intravitreal ranibizumab with or without photodynamic therapy for polypoidal choroidal vasculopathy. Acta Ophthalmol. 2016; 94(8):e765-e771. DOI: 10.1111/aos.13130. View

Kleiner R, Brucker A, Johnston R . The posterior uveal bleeding syndrome. Retina. 1990; 10(1):9-17. View

Qian T, Li X, Zhao M, Xu X . Polypoidal choroidal vasculopathy treatment options: A meta-analysis. Eur J Clin Invest. 2017; 48(1). PMC: 5771464. DOI: 10.1111/eci.12840. View

Oishi A, Kojima H, Mandai M, Honda S, Matsuoka T, Oh H . Comparison of the effect of ranibizumab and verteporfin for polypoidal choroidal vasculopathy: 12-month LAPTOP study results. Am J Ophthalmol. 2013; 156(4):644-51. DOI: 10.1016/j.ajo.2013.05.024. View

Oishi A, Miyamoto N, Mandai M, Honda S, Matsuoka T, Oh H . LAPTOP study: a 24-month trial of verteporfin versus ranibizumab for polypoidal choroidal vasculopathy. Ophthalmology. 2014; 121(5):1151-2. DOI: 10.1016/j.ophtha.2013.12.037. View

10.

Kikushima W, Sakurada Y, Sugiyama A, Tanabe N, Kume A, Iijima H . Comparison of initial treatment between 3-monthly intravitreal aflibercept monotherapy and combined photodynamic therapy with single intravitreal aflibercept for polypoidal choroidal vasculopathy. Graefes Arch Clin Exp Ophthalmol. 2016; 255(2):311-316. DOI: 10.1007/s00417-016-3467-y. View

11.

Lu X, Sun X . Profile of conbercept in the treatment of neovascular age-related macular degeneration. Drug Des Devel Ther. 2015; 9:2311-20. PMC: 4410828. DOI: 10.2147/DDDT.S67536. View

12.

Stewart M . Extended Duration Vascular Endothelial Growth Factor Inhibition in the Eye: Failures, Successes, and Future Possibilities. Pharmaceutics. 2018; 10(1). PMC: 5874834. DOI: 10.3390/pharmaceutics10010021. View

13.

Farooq A, Frazier H, Marcus W, Fechter C, Singh H, Marcus D . Intravitreal Aflibercept for Neovascular Polypoidal Choroidal Vasculopathy in a Predominantly Non-Asian Population: RIVAL Results. Ophthalmic Surg Lasers Imaging Retina. 2017; 48(1):34-52. DOI: 10.3928/23258160-20161219-05. View

14.

Yoneda A, Wakiyama H, Kurihara J, Kitaoka T . Initial treatment for polypoidal choroidal vasculopathy: Ranibizumab combined with photodynamic therapy or fixed-dosing aflibercept monotherapy. Eur J Ophthalmol. 2019; 30(6):1473-1479. DOI: 10.1177/1120672119871886. View

15.

Nagai N, Suzuki M, Minami S, Kurihara T, Kamoshita M, Sonobe H . Dynamic changes in choroidal conditions during anti-vascular endothelial growth factor therapy in polypoidal choroidal vasculopathy. Sci Rep. 2019; 9(1):11389. PMC: 6684594. DOI: 10.1038/s41598-019-47738-9. View

16.

Hosokawa M, Morizane Y, Hirano M, Kimura S, Kumase F, Shiode Y . One-year outcomes of a treat-and-extend regimen of intravitreal aflibercept for polypoidal choroidal vasculopathy. Jpn J Ophthalmol. 2016; 61(2):150-158. DOI: 10.1007/s10384-016-0492-7. View

17.

Arakawa A, Inoue M, Sato S, Yamane S, Kadonosono K . Efficacy of intravitreal aflibercept injections for Japanese patients with polypoidal choroidal vasculopathy. Clin Ophthalmol. 2017; 11:797-802. PMC: 5415008. DOI: 10.2147/OPTH.S129164. View

18.

Liu L, Tham Y, Wu J, Yue S, Cheng C . Photodynamic therapy in combination with ranibizumab versus ranibizumab monotherapy for polypoidal choroidal vasculopathy: A systematic review and meta-analysis. Photodiagnosis Photodyn Ther. 2017; 20:215-220. DOI: 10.1016/j.pdpdt.2017.09.008. View

19.

Yamamoto A, Okada A, Kano M, Koizumi H, Saito M, Maruko I . One-Year Results of Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy. Ophthalmology. 2015; 122(9):1866-72. DOI: 10.1016/j.ophtha.2015.05.024. View

20.

Lai K, Li Y, Zhou L, Zhong X, Huang C, Xu F . Comparison of the effects of photodynamic therapy, intravitreal ranibizumab and combination for polypoidal choroidal vasculopathy under 1 + PRN regimen. BMC Ophthalmol. 2018; 18(1):144. PMC: 6011514. DOI: 10.1186/s12886-018-0801-7. View